Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17396258 | 0.77 | NOS3 (0.49) | NOS3NOS1NOS2 | |
| SCHEMBL17396235 | 0.72 | HTR3E (0.48) | MAPK1QRFPR | |
| SCHEMBL17780006 | 0.72 | KDM1A (0.58) | KDM1AKCNH2KDM1BMEN1KMT2A | |
| SCHEMBL17396335 | 0.71 | HDAC8 (0.47) | KDM1AKCNH2KDM1BHDAC8HDAC6 | |
| SCHEMBL25384548 | 0.71 | KDM1A (0.45) | KDM1AKCNH2KDM1BKMT2AHDAC6 | |
| SCHEMBL20244317 | 0.71 | KDM1A (0.45) | KDM1AKCNH2KDM1BKMT2AHDAC6 | |
| SCHEMBL30509229 | 0.71 | KDM1A (0.45) | KDM1AKCNH2KDM1BKMT2AHDAC6 | |
| SCHEMBL17396077 | 0.67 | MAOA (0.42) | KDM1AIDO1KLKB1 | |
| SCHEMBL20596701 | 0.66 | KDM1A (0.55) | KDM1AKCNH2KDM1BHDAC8HDAC6 | |
| SCHEMBL26991545 | 0.65 | KDM1A (0.53) | KDM1AKCNH2KDM1BCYP2C9HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3164380-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885KCNH2 2447/4885KDM1B 1/4885 |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885KCNH2 2447/4885KDM1B 1/4885 |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885KCNH2 2447/4885KDM1B 1/4885 |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885KCNH2 2447/4885KDM1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.